Navigation Links
Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
Date:11/8/2011

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 8, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two Phase 2 studies evaluating the combination of the company's protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive genotype-1 (GT1) hepatitis C virus (HCV) patients.  The results from the SILEN-C3 and SILEN-C1 studies show that BI 201335 may have the potential to shorten the duration of treatment compared to PegIFN/RBV for a large portion of patients, as well as improve the likelihood of viral cure for patients with characteristics that make their HCV more difficult to treat.  These data were presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, CA.  Phase 3 studies evaluating BI 201335 in various regimens and patient types are ongoing.

"Shortening the length of treatment is among the goals we have at Boehringer Ingelheim as we seek to innovate a new treatment option for HCV patients.  We are encouraged to see that the SILEN-C3 study results suggest that treatment with BI 201335 beyond 12 weeks may not be needed for treatment-naive patients who had an extended rapid viral response," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.  "The SILEN-C1 subgroup results from the more difficult-to-treat patient types also are promising.  We look forward to results from our ongoing Phase 3 program with BI 201335."

(Abstract #36) SILEN-C3:  Treatment for 12 or 24 Weeks with BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin (P/R) in Treatment-Naive Patients with Chronic Genotype-1 HCV Infection

The results from SILEN-C3 indicate that among patients who had an extended rapid viral response (eRVR), 12 weeks of treatment with
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... octubre de 2014  PneumRx, Inc. ( www.pneumrx.com ... pulmonología intervencional, anunció hoy la conclusión de la ... antes de lo programado. El Estudio Clínico RENEW es ... investigación (IDE) aprobada por la FDA (Administración de ... de reducción de volumen pulmonar PneumRx RePneu, un ...
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... , WILMINGTON, Del. ... System is taking a giant leap forward toward a ... Order Entry (CPOE), technology that makes it easier, more efficient ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090407/DC95299LOGO ) , The system goes live on ...
... , HOFFMAN ESTATES, Ill. , Jan. 28 ... Drug Administration (FDA) has given 510(k) marketing clearance to both ... , The DYNA-LINK system features a next-generation stand-alone device that ... is a thoracolumbar plating system that features multiple types of ...
Cached Medicine Technology:Christiana Care Health System Rolls Out Electronic Computerized Provider Order Entry 2
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, BambooIndustry.com, ... has unveiled its new range of bamboo deckings ... for these natural items; they are now available at ... most people, it is hard to overstate the significance ... of attention to online services. The company’s workers are ...
(Date:10/19/2014)... Having been working in the garment industry for ... needs. According to James, one of the company’s top designers, ... with high-low skirts that add beauty to them. Chiffon floor ... has unveiled its new selection of 2014 long prom dresses. ... new items are available in over 20 popular designs. The ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... for Labor Law Reform , , ... have reached a tentative agreement with hospital management for a new ... workers, and an average wage increase of 33 percent over four ... contract would cap more than a year of bargaining that followed ...
... team led by the La Jolla Institute for Allergy ... important role of natural killer (NK) T cells in ... blood cells are central to clearing the bacterial infection ... with Lyme disease. , "Our findings are that the ...
... Dec. 3 Ten students pursuing health care careers in ... scholarships from the National Hispanic Health Foundation (NHHF) at the ... p.m.December 4 at the New York Marriott Marquis Hotel. ... was supported by United Health Foundation, who donated $15,000 for ...
... 3 Blue Cross & Blue Shield of Rhode,Island (BCBSRI) ... a new five-year agreement, which ensures that CNE will remain ... CNE hospitals (Kent,Women & Infants, and Butler) and the VNA ... According to BCBSRI President and CEO James E. Purcell, ...
... 3 A patient who was surgically implanted,with Medtronic,s ... Medtronic, suffocated due to severe throat and neck swelling, ... Page Perry, LLC who filed the lawsuit,in California along ... The Complaint alleges, among other things, ...
... the procedure impairs healthy immune response , , WEDNESDAY, Dec. ... are at increased risk of asthma, according to Swiss ... of nearly 3,000 infants. , By the time they ... children had been diagnosed with asthma for which they,d ...
Cached Medicine News:Health News:Healthcare Workers Reach Tentative Agreement With Enloe Medical Center 2Health News:Researchers identify cell group key to Lyme disease arthritis 2Health News:Researchers identify cell group key to Lyme disease arthritis 3Health News:NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:C-Section Might Boost Baby's Asthma Risk 2
9 mm wide tip. 35 mm from angle to tip....
4 mm wide tip....
5 mm wide tip....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Medicine Products: